Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) is advancing a novel approach to cancer treatment, according to Chief Medical Officer Dr. Islam Mohamed, who appeared on the IBN BioMedWire Podcast to discuss the company's lead drug candidate ONC010 and its planned first-in-human clinical program. The podcast, part of BioMedWire's specialized communications platform for the biotechnology and life sciences sectors, provided a platform for Mohamed to explain the science behind ONC010 and why it represents a potentially significant development in oncology.
ONC010 targets polynucleotide kinase phosphatase (PNKP), a DNA repair enzyme that plays a critical role in maintaining genomic integrity. By inhibiting PNKP, the drug aims to disrupt cancer cells' ability to repair DNA damage, ultimately leading to cell death. Mohamed highlighted two key selectivity mechanisms that differentiate ONC010 from conventional therapies. The first is synthetic lethality, which is designed to limit the drug's lethality to cancer cells that have lost PTEN or SHP-1, two tumor suppressor proteins commonly mutated or deleted in various cancers. This approach could spare healthy cells and reduce side effects. The second mechanism is nanoparticle delivery, which is intended to concentrate the drug within tumor tissue, further enhancing its specificity and potency.
These mechanisms are supported by preclinical research conducted at the University of Alberta. In those studies, the nano-formulated PNKP inhibitor demonstrated single-agent antitumor activity, was tolerated at tested doses, and prolonged survival relative to controls. Such results are encouraging because they suggest that ONC010 could be effective as a monotherapy, without the need for combination with other agents that might add toxicity. The company holds an exclusive worldwide licence to patented technology directed to the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response.
The implications of this announcement are significant for the oncology field. If ONC010 proves successful in human trials, it could offer a new treatment option for patients whose tumors have lost PTEN or SHP-1, which includes subsets of breast, prostate, and other cancers. The synthetic lethality approach is particularly promising because it exploits specific genetic vulnerabilities in cancer cells, potentially leading to precision medicines with better safety profiles. Moreover, the nanoparticle delivery system could improve drug accumulation in tumors, addressing a common challenge in cancer therapy. As Onco-Innovations prepares for its first-in-human clinical program, the company is positioning itself at the forefront of DNA damage response therapeutics, a rapidly growing area of cancer research.
For investors and industry observers, the podcast and the underlying science underscore Onco-Innovations' commitment to pioneering research. The company's mission is to pursue the prevention and treatment of cancer through innovative solutions, and ONC010 is a testament to that goal. The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF. To view the full press release, visit https://ibn.fm/XgpMR. BioMedWire, which hosted the podcast, is a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, and is part of the Dynamic Brand Portfolio @ IBN. For more information, visit https://www.BioMedWire.com. The platform's broad reach and tailored communications solutions help private and public companies gain recognition and brand awareness among investors, influencers, and the general public.
